Switzerland· 69230003
Nexpovio 20 mg, Filmtabletten
A selinexor product containing selinexorum, registered in Switzerland by Stemline Therapeutics Switzerland GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Selinexor is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XX66 (selinexor), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Selinexor · ATC L01XX66
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of selinexor costs, country by country.
Normalised to the WHO defined daily dose (18.6 mg), the median price runs from $0.99 in France to $402.73 in Switzerland — a ×406 gap.
- Switzerland: $402.73 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Selinexor · price per daily dose (18.6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$402.73
- FR France$0.99
The record
At a glance
Swissmedic (Switzerland)- Active substance
- selinexorum
- Manufacturer
- Stemline Therapeutics Switzerland GmbH
- Country
- Switzerland (CH)
- ATC code
- L01XX66
- ATC class
- Selinexor
- Defined daily dose
- 18.6 mg, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680692300034Blist 16 StkCHF 5746.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
72 interactions on record for selinexor.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selinexor · interactions on record
72 records
- 29 severe
- 43 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selinexor in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNEXPOVIOStemline Therapeutics B.V., Amsterdam
- FinlandNEXPOVIOStemline Therapeutics B.V.
- FranceNEXPOVIO 20 mg, comprimé pelliculéSTEMLINE THERAPEUTICS (PAYS-BAS)
- IrelandNEXPOVIO 20 mg film-coated tabletsKaryopharm Europe GmbH
- IcelandNEXPOVIOStemline Therapeutics B.V.
- NetherlandsNEXPOVIO 20 mg, filmomhulde tabletStemline Therapeutics B.V.
- PolandNEXPOVIOStemline Therapeutics B.V.
- SwedenNEXPOVIO 20 mg Filmdragerad tablettStemline Therapeutics B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nexpovio
- Liechtenstein · Nexpovio
- Norway · Nexpovio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5484fda7-0ffd-43e6-98b3-625f58fbbb07 GET /v1/drugs/5484fda7-0ffd-43e6-98b3-625f58fbbb07?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "selinexorum 20 mg",
"valid_from": "2026-02-01",
"limitations": "[{\"description\":\"Nur nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Eine Kostengutsprache hat den entsprechenden Indikationscode (21811.01) zu enthalten.<br>\\nNEXPOVIO wird in Kombination mit Dexamethason für die Behandlung des Multiplen Myeloms bei erwachsenen Patienten, die zuvor mindestens vier Therapielinien erhalten haben und deren Erkrankung gegenüber mindestens zwei Proteasom-Inhibitoren, zwei immunmodulatorischen Arzneimitteln und einem monoklonalen Anti-CD38-Antikörper refraktär ist und bei denen unter der letzten Therapie eine Progression der Erkrankung aufgetreten ist, vergütet.<br>Nur bis zur Progression der Krankheit.<br>\\nZudem gelten folgende Vergütungskriterien:<br>\\n- Mindestens eine messbare Erkrankung gemäss den Kriterien der IMWG<br>\\n- ECOG Performance-Status von ≤ 2<br>\\n- ausreichende hepatische, renale und hämatopoetische Funktion<br>\\n<br>\\nDie Zulassungsinhaberin Stemline Therapeutics Switzerland GmbH erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung NEXPOVIO einen Betrag von Fr. 934.92 zurück. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21811.01<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21811.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-02-01\",\"validTo\":\"2028-01-31\"}]",
"galenic_form": "Filmtabl 20 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2026-02-01",
"self_retention_pct": 10
}See everything about selinexor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.